Overview Oral Valganciclovir Versus Valacyclovir Status: Completed Trial end date: 2006-07-01 Target enrollment: Participant gender: Summary To determine if the rate of cytomegalovirus reactivation during treatment with alemtuzumab (Campath) is reduced by the use of valganciclovir prophylaxis. Phase: Phase 2 Details Lead Sponsor: M.D. Anderson Cancer CenterCollaborator: Roche Pharma AGTreatments: AcyclovirAlemtuzumabGanciclovirValacyclovirValganciclovir